Newbury Pharmaceuticals
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.
Newbury Pharmaceuticals Secures Generic Approval for Melatonin Newbury
Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Melatonin Newbury 2 mg prolonged-release tablets in Finland as the first country in a Nordic registration procedure. Approvals in Sweden, Norway and Denmark are expected to follow upon finalized national reviews.
Melatonin Newbury is indicated as monotherapy for the short-term treatment of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over. Melatonin Newbury is a generic version of Circadin. The current annual value of the Nordic market is estimated to be 11 MEUR according to DLMI Nordic Pharma Insights.
“The successful approval of Melatonin Newbury highlights Newbury's capability to offer a diverse and comprehensive portfolio and it is also Newbury’s second marketing authorization in Finland” says Mr Lars Minor CEO of Newbury
| Datum | 2025-08-11, kl 10:00 |
| Källa | MFN |